Comparative analysis of Tsc1 and Tsc2 single and double radial glial cell mutants

Journal of Comparative Neurology

Volumn 521, Issue 16, 2013, Pages 3817-3831

  Mietzsch, Ulrike ^a   McKenna, James ^b   Reith, R Michelle ^c   Way, Sharon W ^d   Gambello, Michael J ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Whitehead Biomedical Research Building ^*  (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Brain; Genotype; Hamartin; Phenotype; Tuberin

Indexed keywords

HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN KINASE B; TUBERIN;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN GROWTH; BRAIN REGION; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GLIA CELL; GLIAL PRECURSOR CELL; HETEROTOPIA; HIPPOCAMPUS; MALE; MORTALITY; MOUSE; MYELINATION; NEGATIVE FEEDBACK; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PERINATAL PERIOD; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; STRATUM PYRAMIDALE; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS;

BRAIN; GENOTYPE; HAMARTIN; PHENOTYPE; TUBERIN;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; BRAIN; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEUROGLIA; TUMOR SUPPRESSOR PROTEINS;

EID: 84892895777     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.23380     Document Type: Article

References (43)

1. Au K, Hebert A, Roach E, Northrup H. 1999. Complete inactivation of the TSC2 gene leads to formation of hamartomas. Am J Hum Genet 65:1790-1795.
2. Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, Wheless JW, Baumgartner JE, Roa BB, Wilson CM, Smith-Knuppel TK, Cheung MY, Whittemore VH, King TM, Northrup H. 2007. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 9:88-100.
3. Cai J, Chen Y, Cai WH, Hurlock EC, Wu H, Kernie SG, Parada LF, Lu QR. 2007. A crucial role for Olig2 in white matter astrocyte development. Development 134:1887-1899.
4. Carson R, Van Nielen D, Winzenburger P, Ess K. 2012. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. Neurobiol Dis 45:369-380.
5. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin- Kowalik J, Kotulska K, Kwiatkowski DJ. 2004. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 63:1236-1242.
6. Consortium. 1993. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75: 1305-1315.
7. Crino PB. 2004. Molecular pathogenesis of tuber formation in tuberous sclerosis complex. J Child Neurol 19:716-725.
8. Crino PB, Nathanson KL, Henske EP. 2006. The tuberous sclerosis complex. N Engl J Med 355:1345-1356.
9. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, EgelhoffJC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ. 2001. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 68:64-80.
10. Dibble C, Asara J, Manning B. 2009. Characterization of rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 29:5657-5670.
11. DiMario FJ Jr. 2004. Brain abnormalities in tuberous sclerosis complex. J Child Neurol 19:650-657.
12. DiNardo A, Kramvis I, Cho N, Sadowski A, Meikle L, Kwiatkowski D, Sahin M. 2009. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner. J Neurosci 29:5926-5937.
13. El-Hashemite N, Zhang H, Henske E, Kwiatkowski D. 2003. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 361:1348-1349.
14. Fonseca BD, Alain T, Finestone LK, Huang BP, Rolfe M, Jiang T, Yao Z, Hernandez G, Bennett CF, Proud CG. 2011. Pharmacological and genetic evaluation of proposed roles of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), extracellular signalregulated kinase (ERK), and p90(RSK) in the control of mTORC1 protein signaling by phorbol esters. J Biol Chem 286:27111-27122.
15. Gomez MR (ed.). 1999. Tuberous sclerosis complex, 3rd ed. New York: Oxford University Press.
16. Goto J, Talos DM, Klein P, Qin W, Chekaluk YI, Anderl S, Malinowska IA, Di Nardo A, Bronson RT, Chan JA, Vinters HV, Kernie SG, Jensen FE, Sahin M, Kwiatkowski DJ. 2011. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci U S A 108:E1070-1079.
17. Han J, Sahin M. 2011. TSC1/TSC2 signaling in the CNS. FEBS Lett 585:973-980.
18. Henske E, Wessner L, Golden J, Scheithauser b, Vortmeyer A, Zhuang Z, Klein-Szanto A, Kwiatkowski D, Yueng R. 1997. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 151:1639-1647.
19. Huang J, Manning B. 2009. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37:217-222.
20. Huang J, Dibble C, Matsuzaki M, Manning B. 2008. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 28:4101-4115.
21. Jones A, Daniells C, Snell R, Tachataki M, Idziaszczyk S, Krawczak M, Sampson J, Cheadle J. 1997. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Mol Genet 6:2155-2161.
22. Jones A, Shyamsundar M, Thomas M, Maynard J, Idziaszczyk S, Tomkins S, Sampson J, Cheadle J. 1999. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 64:1305-1315.
23. Lewis J, Thomas H, Murphy K, Sampson J. 2004. Genotype and psychological phenotype in tuberous sclerosis. J Med Genet 41:203-207.
24. Li H, Adachi Y, Yamamoto H, Min Y, Ohashi H, Ii M, Arimura Y, Endo T, Lee CT, Carbone DP, Imai K, Shinomura Y. 2011. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer 117:3135-3147.
25. Makki M, Chugani D, Janisse J, Chugani H. 2007. Characteristics of abnormal diffusivity in normal-appearing white matter investigated with diffusion tensor MR imaging in tuberous sclerosis comnplex. Am J Neuroradiol 28:1662-1667.
26. Malatesta P, Hack MA, Hartfuss E, Kettenmann H, Klinkert W, KirchhoffF, Gotz M. 2003. Neuronal or glial progeny: regional differences in radial glia fate. Neuron 37:751-764.
27. Meikle L, Talos DM, Onda H, Pollizzi K, Rotenberg A, Sahin M, Jensen FE, Kwiatkowski DJ. 2007. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 27:5546-5558.
28. Park JH, Arakawa-Takeuchi S, Jinno S, Okayama H. 2011. Rho-associated kinase connects a cell cycle-controlling anchorage signal to the mammalian target of rapamycin pathway. J Biol Chem 286:23132-23141.
29. Plank T, Yeung R, Henske E. 1998. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 58:4766-4770.
30. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, Tsun ZY, Cowley GS, Barretina J, Kalaany NY, Hsu PP, Ottina K, Chan AM, Yuan B, Garraway LA, Root DE, Mino-Kenudson M, Brachtel EF, Driggers EM, Sabatini DM. 2011. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476:346-350.
31. Potter CJ, Huang H, Xu T. 2001. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105: 357-368.
32. Qin W, Chan J, Vinters H, Mathern G, Franz D, Taillon B, Bouffard P, Kwiatkowski D. 2012. Analysis of TSC cortical tubers by deep sequencing ofr TSC1, TSC2 and KRAS demonstrates that small hit mutation in these genes are rare events. Brain Pathol 20:1096-1105.
33. Ridler K, Bullmore E, De Vries P, Suckling J, Barker G, Meara S, Williams S, Bolton P. 2001. Widespread anatomical abnormalities of grey and white matter structure in tuberous sclerosis. Psychol Med 31:1437-1446.
34. Rosner M, Hanneder M, Siegel N, Valli A, Hengstschlager M. 2008. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat Res 658:234-246.
35. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievet A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A. 2005. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting genotypephenotype correlations and comparison of diagnostic techniques in Tuberous Sclerosis Complex. Eur J Hum Genet 13:731-741.
36. Sarbassov D, Ali S, Sabatini D. 2005. Growing roles for the mTOR pathway. Curr Opin Cell Biol 17:596-603.
37. Tyler W, Gangoli N, Gokina P, Kim H, Covey M, Levison S, Wood T. 2009. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci 29:6367-6378.
38. Uhlmann EJ, Wong M, Baldwin RL, Bajenaru ML, Onda H, Kwiatkowski DJ, Yamada K, Gutmann DH. 2002. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 52:285-296.
39. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Sampson JR, Reeve MP, Richardson P, Wilmer F, Munro C, Hawkins TL, Sepp T, Ali JB, Ward S, Green AJ, Yates JR, Kwiatkowska J, Henske EP, Short MP, Haines JH, Jozwiak S, Kwiatkowski DJ. 1997. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:805-808.
40. Way S, McKenna J, Mietzsch U, Reith R, Wu H, Gambello M. 2009. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Genet 18:1252-1265.
41. Wu M, Liu H, Fannin J, Katta A, Wang Y, Arvapalli RK, Paturi S, Karkala SK, Rice KM, Blough ER. 2010. Acetaminophen improves protein translational signaling in aged skeletal muscle. Rejuven Res 13:571-579.
42. Yang S, Xiao X, Meng X, Leslie KK. 2011. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PloS One 6:e26343.
43. Zeng L, Rensing N, Zhang B, Gutmann D, Gambello M, Wong M. 2011. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet 20:445-454.